NIDO (Boston, MA) is a medical device company developing SEPIA, an innovative solution for epicardial ablation of ventricular tachycardia (VT), based on technology developed at Boston Children's Hospital. It has been co-founded by Pedro del Nido, Chairman of Cardiovascular Surgery and Professor at Harvard Medical School, and Nikolay Vasilyev, Medical Director for Surgicals Portfolio at Pfizer. SEPIA will allow real-time visualization of the epicardial surface and provide angle and force control to an ablation catheter. Ultimately, it will reduce complications and improve ablation efficiency, leading to decrease recurrence of VT.